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Abstract
BACKGROUND: Since the WHO declaration of COVID-19 being a global pandemic, the population in general and 
health-care providers, in particular, became under extraordinary pressure that remarkably impacts their decisions at 
multiple levels as all of us should make decisions quickly while being uncertain in many times.
CASE REPORT: We are reporting a 64-year-old lady with a medical history of atrial fibrillation and mitral regurgitation 
that treated with digoxin and warfarin therapy, she was suspected to be a COVID-19 case and prescribed empirical 
hydroxychloroquine and azithromycin combination without proper adjustment of her baseline therapy, accordingly 
she developed adverse effect of this combination in the form of digoxin toxicity and long QT, this case highlights how 
this unprecedented pandemic affects the decision-making of physicians.
CONCLUSION: We should be critical and vigilant in making a decision of prescription or marketing non-evidence-
based therapy, and when we are obligated for this decision, we should take all precautions to minimize the adverse 
effects of these drugs.
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Background
Since the WHO declaration of COVID-19 being 
global pandemic on March 11, 2020 [1], the population in 
general and health-care providers, in particular, became 
under extraordinary pressure and in state of panic that 
remarkably impacts their decisions at multiple levels 
as all of us should make decisions quickly while being 
uncertain in many times. Amidst this unprecedented crisis, 
initial researchers found treating COVID-19 pneumonia 
with hydroxychloroquine (HCQ) might increase the rate 
of treatment success, shorten hospitalization, as well 
as improve outcomes [2]. Others suggested that there 
was a synergistic effect of the combination of HCQ 
and azithromycin (AZ) in decreasing viral load and 
recommended its use to cure COVID-19 patients with 
subsequent transmission control; however, the study 
pointed to possible prolongation of QT interval with use 
of this combination [3]. On March 28, 2020, FDA issued 
an emergency use authorization that allowed for the 
use of the drugs to treat patients with COVID-19 [4]. 
Accordingly, physicians started using this combination 
therapy worldwide in the hope to decrease this pandemic 
burden. We are reporting a patient with multiple 
comorbidities who was suspected to be a COVID-19 
case and prescribed empirical HCQ and AZ combination 
then developed adverse effect of this therapy, this case 
highlights how COVID-19 pandemic affects the decision-
making of physicians.
Case Presentation
A 64-year-old lady had history of hypertension, 
and moderate mitral regurgitation (MR) due to mitral valve 
prolapse and paroxysmal atrial fibrillation, for which she 
was prescribed 1 month before presentation a digoxin 
tablet 0.25 mg and a warfarin tablet 5 mg; both once daily.
During peak of country lockdown and COVID-19 
pandemic panic in Iraq at March 26, 2020, the patient was 
presented to the ER of a teaching hospital complaining 
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of nausea and vomiting, she denied fever and respiratory 
symptoms; however, in the era of COVID-19 pandemic 
the treating physician requested chest CT scan which 
showed bilateral ground-glass opacity Figure 1, so 
COVID-19 was his provisional diagnosis. She sought 
the second opinion by consulting other physician who 
prescribed HCQ (200 mg twice daily) and AZ (500 mg 
once daily) without adjusting the baseline therapy, and 
he recommended her being self-quarantined at home.
Figure 1: Initial chest computed tomography scan showing bilateral 
ground-glass infiltrates (in the first hospital)
Two days later, the patient was presented to 
our facility complaining from abdominal pain, nausea, 
and vomiting, her examination was remarkable only for 
heart rate HR of 35 bpm; on further inquiry, she denied 
syncope or presyncope.
New electrocardiography (ECG) revealed 
complete heart block (CHB) with escape junctional 
rhythm, diffuse ST-depression with reverse tick 
appearance, with long QT interval, these changes were 
new compared to a previous ECG done 10 days before 
presentation (on an outpatient clinic follow-up visit 
for her valve problem), Figure 2a-d. Her biochemical 
profile revealed elevated renal indices: Blood urea was 
115 mg/dL, serum creatinine was 2.3 mg/dL, electrolyte 
and liver function tests were normal, and her INR was 
1.6. The second chest CT scan was done again as she 
did not inform her treating team about the first chest CT 
that was done earlier, the second CT scan confirmed 
the same findings, so the patient was presumed to be a 
COVID-19 case based on her chest CT findings.
The main provisional diagnosis was digoxin 
toxicity induced by her impaired renal function and 
interaction of digoxin with additive potentiation of 
HCQ, AZ, and warfarin resulting in long QT and CHB. 
Accordingly, the patient was admitted to a quarantined 
CCU where she was the only patient there, nasal and 
throat swabs were taken and sent for polymerase chain 
reaction (PCR) for severe acute respiratory syndrome 
coronavirus-2 (SARS-CoV2), she was kept under 
monitoring, while hydroxychloroquine, azithromycin and 
digoxin were all withheld. She was treated conservatively 
with frequent atropine injections; 0.6 mg as needed. At 
first in-hospital day, the patient heart rate was 30 bpm, 
so resident on-call gave her frequent atropine injections 
(up to 3 mg), few hours later, the patient developed 
confusion (at this point heart rate was 60 bpm), brain CT 
was unremarkable, the treating physician considered 
this confusion as an adverse effect of atropine. Hence, 
the patient was kept under observation, and she 
regained full consciousness 8 h later.
Twenty-four hours later, the result of PCR 
was negative for SARS-CoV2. An echocardiography 
was done to assess her valve problem, and it showed 
moderate eccentric MR with prolapsing anterior mitral 
valve leaflet, good left ventricular function.
The patient was responding to conservative 
measures with HR returning to 60 bpm with a junctional 
rhythm. She was discharged after 5 days on April 2, 
2020. Then, she was followed up on an outpatient 
basis for the next 10 days, she denied any symptoms 
and returned to sinus rhythm with a rate of (67) bpm, 
Figure 3.
Figure 3: Electrocardiography on follow up visit 10 days after discharge, 
showing a heart rate of 67 bpm and nonspecific ST-T changes
Figure 2: Serial electrocardiography (ECG) of the patient (a) Baseline 
ECG (before presentation) with normal sinus rhythm. (b) Complete 
heart block with the regular ventricular response, generalized down 
sagging ST depression with QTc interval of 411 msec (at presentation). 
(c) Second in-hospital day ECG with a heart rate of 75 bpm after 
atropine therapy and QTc of 408 msec. (d) Third in-hospital day ECG 
showing complete heart block with a junctional escape rhythm
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Discussion
Digoxin is a cardiac glycoside derived from the 
purple foxglove flower, it is a commonly prescribed drug 
in practice for heart failure and/or atrial fibrillation [5]. 
It has very narrow therapeutic index with very wide 
spectrum of drugs interactions, which made digoxin 
toxicity once very common; however, it is declining in 
modern era due to use of alternative drugs in heart 
failure with greater impact on prognosis and use of more 
accurate dosing methods [6], among potential causes 
for digoxin toxicity are coprescription of drugs that 
increase digoxin absorption or decrease digoxin renal 
excretion without proper adjustment of digoxin dosage 
[7]. Macrolide antibiotics are such examples as known 
to increase digoxin levels by inhibition of P-glycoprotein 
by reducing energy-dependent digoxin transport from 
enterocytes into intestinal lumen and limiting transport 
into the lumen of the nephron [8], [9]. Despite AZ less 4 
times than clarithromycin to cause digoxin toxicity, it still 
can remarkably cause digoxin toxicity [10] as occurred 
in this patient. HCQ also reported to increase digoxin 
level mostly due to digoxin displacement from its binding 
site in tissues or by decreasing renal clearance [11], 
[12]. Furthermore, this patient was on warfarin therapy 
which was reported to cause significant interaction with 
digoxin [13], [14], such polypharmacy was the main 
driving cause for digoxin toxicity here especially in view 
of renal impairment. Digoxin toxicity can manifest as 
gastrointestinal complaints such as nausea, vomiting, 
and abdominal pain as occurred in this patient or visual 
disturbance such as yellow vision and neurological 
manifestations such as headache, lethargy confusion, 
dizziness, and delirium [15], [16]. Despite this patient 
had confusion that could be explained by digoxin 
toxicity or CHB, we think that atropine use can explain 
this neurological manifestation as atropine was reported 
to cause such adverse effect especially that the onset 
of confusion was after atropine administration and her 
accepted heart rate at time of confusion contradicted 
CHB as an explanation for this manifestation 
[17], [18]. Digoxin toxicity can cause many ECG 
changes, including frequent PVC, junctional tachycardia, 
junctional rhythm, heart block, atrial fibrillation, atrial 
flutter, premature atrial contractions, sinus arrest, sinus 
bradycardia or tachycardia, wandering pacemaker, 
ventricular tachycardia, or ventricular fibrillation [19]. It is 
noteworthy to mention that scooping ST-T changes and 
reverse tick sign in ECG of this patient are considered 
digitalis effect, that is, they can occur with digoxin in a 
therapeutic range not necessarily in the toxic range [16]. 
This patient had CHB with a junctional escape rhythm 
signifying cardiotoxicity from digoxin. She did not only 
have digoxin toxicity due to multiple drugs interaction 
and renal impairment but also prolonged QT interval 
due to combination of HCQ and AZ which were reported 
to cause prolonged QT due to blocking of human 
ether-a-go-go-related gene potassium canal resulting 
in slow cardiac repolarization [20]. Drug- induced 
long QT is more to occur in elderly, females, patients 
with hypoxia, cardiovascular diseases, and metabolic 
derangement [21], [22]. This patient is a female with 
structural heart disease and on digoxin and warfarin 
which can interact remarkably with HCQ-AZ combination, 
all that resulted in higher risk for developing long QT. 
Measurement of serum digoxin level and FAB treatment 
is not available in our facility making the main treatment 
of digoxin toxicity in this patient by withholding the 
offending drugs with supportive measures like atropine. 
Another interesting point, in this case, was the ground-
glass opacity finding in chest CT scan, as COVID-19 
mainly was excluded by negative PCR, with no clinical 
evidence of other pulmonary infections in term of fever 
nor cough, despite acute MR was reported to cause 
ground-glass opacity [23], no literature reported such 
finding in chronic MR; however, we think that subclinical 
pulmonary congestion can be a possibility for such 
finding as volume overload was reported to cause such 
radiological manifestation [24].
This patient was not confirmed to be a 
COVID-19 case nor being critical enough to justify 
prescribing non-evidence-based drugs such as AZ and 
HCQ, especially in view of other drugs with potential 
interactions like digoxin or warfarin without proper 
dosage adjustment.
During this emergency pandemic, it is well 
understood that FDA should act quickly and effectively, 
trying to facilitate all steps toward fulfilling the eager 
population expectation to find the proper treatment 
for COVID-19, including experimental therapy based 
on no proper randomized trials. However, we, as 
physicians, academics, and researchers, should be 
critical and vigilant in making a decision of prescription 
or marketing non-evidence-based therapy and when 
we are obligated for this decision, we should take all 
precautions to minimize adverse effects of these drugs.
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